14.00-14.05
Introduction and aims of webinar
Chairs: Justin Davies, Marco Cappa
Successful hGH administration can transform the life of a child who was destined to live with significant short stature into an adolescent facing adulthood confidently with height within the normal range. The aims of this webinar are to discuss how to optimize benefit from rhGH, which is dependent on three key factors.
Firstly, investigation must identify the children with GH deficiency who are likely to respond best to rhGH treatment. Secondly, it is now clear that adherence to the standard hGH injection regimen is subnormal in a large number of patients, impacting their clinical growth response. Understanding the causes and psychopathology of poor adherence is a major component of hGH management, and clinician and care team input and support to address this issue is crucial to treatment success. Finally, a major advance has recently occurred with the development and marketing of LAGH leading to weekly, rather than daily administration. As clinical experience with this new therapy remains limited, this webinar will provide information on the new therapies, and an opportunity for discussion with clinicians who have experience of the new treatments.
After attending the live webinar participants will be able to:
Pediatricians, endocrinologists and clinicians involved in growth management.
The official language of this live educational activity will be English.
The Priorities for an optimal response to Pediatric Growth Hormone (hGH), Rome, Italy, 05/05/2023-05/05/2023 has been accredited by the European Accreditation Council for Continuing Medical Education (EACCME®) with 1 European CME credit (ECMEC®). Each medical specialist should claim only those hours of credit that he/she actually spent in the educational activity.
Through an agreement between the Union Européenne des Médecins Spécialistes and the American Medical Association, physicians may convert EACCME® credits to an equivalent number of AMA PRA Category 1 CreditsTM. Information on the process to convert EACCME® credit to AMA credit can be found at www.ama-assn.org/education/earn-credit-participation-international-activities.
Live educational activities, occurring outside of Canada, recognised by the UEMS-EACCME® for ECMEC®s are deemed to be Accredited Group Learning Activities (Section 1) as defined by the Maintenance of Certification Program of the Royal College of Physicians and Surgeons of Canada.
The content of the “Priorities for an optimal response to Pediatric Growth Hormone (hGH), Online 5th May 2023” has been certified by the CPD Certification Service as conforming to continuing professional development principles.
Priorities for an optimal response to Pediatric Growth Hormone (hGH)
14.00-14.05
Introduction and aims of webinar
Chairs: Justin Davies, Marco Cappa
14.05-14.25 / L1
Diagnosis of GH deficiency using a balanced clinical, endocrinological and genetic approach to investigate short stature
Martin O. Savage, UK
14.25-14.45 / L2
The realities of adherence to hGH therapy
John Weinman, UK
14.45-15.05 / L3
How long-acting hGH compares in efficacy and safety with daily hGH injections
Cheri Deal, Canada distrusts behaviour abilities defective is. Never at water me might.
15.05-15.25 / Panel discussion
Justin Davies, Richard Ross, Martin Savage, John Weinman, Cheri Deal, Marco Cappa
15.05-15.25 / Panel discussion
Justin Davies, Richard Ross, Martin Savage, John Weinman, Cheri Deal, Marco Cappa
15.25-15.30 / Closing remarks
Richard Ross
Cookie | Duration | Description |
---|---|---|
cookielawinfo-checkbox-analytics | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics". |
cookielawinfo-checkbox-functional | 11 months | The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional". |
cookielawinfo-checkbox-necessary | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary". |
cookielawinfo-checkbox-others | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other. |
cookielawinfo-checkbox-performance | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance". |
viewed_cookie_policy | 11 months | The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data. |
Martin Savage is Emeritus Professor of Paediatric Endocrinology at William Harvey Research Institute, Barts and the London School of Medicine & Dentistry, Queen Mary, University of London. He was head of the Paediatric Endocrine Unit at Barts and the London School of Medicine from 1982 to 2007. He has interests in growth disorders, specifically those with abnormalities in the GH-IGF-1 axis and in phenotype-genotype relationships of GH-IGF-1 axis defects, notably GH resistance. He published the first human case of an IGF-1 gene defect in the New England Journal of Medicine in 1996. His other interests are Cushing’s syndrome and growth in chronic inflammatory diseases. He was General Secretary of the European Society for Paediatric Endocrinology (ESPE) from 1997 to 2004. He has lectured in 61 countries and has published 472 original articles, reviews, textbook chapters and books. In 2007, he was awarded the ESPE Andrea Prader Prize for contributions to paediatric endocrinology and in 2018 he received a Visionary Award from the American Human Growth Foundation. In 2022, he received a Research Excellence Award from the Dr Sulaiman Al Habib Medical Journal in Riyadh, and the British Society of Paediatric Endocrinology & Diabetes James M. Tanner Lifetime Achievement Award. He continues to lecture nationally and internationally.
Justin Davies is a Consultant Paediatric Endocrinologistand Honorary Associate Professorat Southampton Children’s Hospital and the University of Southampton. He is theService Lead for paediatric endocrinology at Southamptonand also leads the Paediatric Metabolic Bone service with a multidisciplinary team dedicated to rare bone disease and childhood osteoporosis. His research interestsinclude secondary osteoporosis, impact of disease on body composition and imprinting disorders.Dr Davies was Chairman of the British Society of Paediatric Endocrinology and Diabetes 2016-2020. He is the service lead for the European Reference Centre -Southampton for Rare Bone Disease and Endocrinology (Growth disorders). His other national roles have included the Secretary of the British Paediatric and Adolescent Bone Group,Treasurer of the British Society of Paediatric Endocrinology and Diabetes.Dr Davies leads an international school for paediatric endocrinology -the European Society for Paediatric Endocrinology, Winter School.
Cheri Deal was Chief of Endocrinology and Diabetes at the Sainte-Justine Mother-Child University, Montreal Hospital until 2020, when she became Emeritus Professor at the University of Montreal, where she continues to teach and maintain her affiliation with the research center. She is also a Pediatric Endocrinology Consultant for the ELNA Tiny Tots Multi-Specialty Pediatric Clinic in Montreal.
Professor Deal’s research interests include the genetics/epigenetics of the GH-IGF axis and rare syndromes including Prader-Willi (PWS) and Turner syndrome. She has contributed to the elucidation of the molecular defects associated with a wide range of rare pediatric endocrine disorders and cancers and participated in clinical studies, most recently as the lead clinical investigator for the phase 3 pivotal trial on long-acting GH, somatrogon and for a phase 3 trial in PWS. She has helped to elaborate clinical practice guidelines aimed at ameliorating outcomes in many endocrine diseases including growth hormone deficiency, PWS and precocious puberty. Professor Deal received the 2013 CSEM Educator of the Year Award and the 2017 Robert Volpé CSEM Distinguished Service Award for her contributions to clinical care, research, administration and teaching. Professor Deal has served as President of the Canadian Pediatric Endocrine Group and the Canadian Society of Endocrinology and Metabolism, as a council member for the Growth Hormone Research Society and the International Society of Endocrinology (ISE), as the Training Director for the Royal College Program in Pediatric Endocrinology and Diabetes for the University of Montreal, and as the site leader for the pan-Canadian Child Health Clinical Scientist Training Program (CCHCSP). She is currently co-chair of the Education Committee of ISE and is on the curriculum committee of CCHCSP (now renamed ENRICH – Empowering Next-generation Researchers in Perinatal and Child Health) and the European Society of Pediatric Endocrinology summer school organizing committee.
Professor Deal has authored more than 155 papers and in 2019, co-edited the textbook Maternal-Fetal and Neonatal Endocrinology.
Richard Ross trained in medicine at The Royal London Hospital (1974-1979) and in Endocrinology at St Bartholomew’s Hospital, London (1983-1988). He was appointed to Sheffield University in 1995 and wasHead of the Academic Unit of Diabetes, Endocrinology and Metabolismand is currently Theme Lead for Diabetes and Endocrinology. He retired from clinical practice in June 2020. Hisresearch and clinical interests are in pituitary and adrenal disease, transition endocrinology and the late effects of cancer. Professor Ross has served on the editorial boards of Clinical Endocrinology (1996-2000), Growth & Growth Factors (1986-2006), Hormones (2004-2018), and J Clin Endocrinol Metab (2010-2014). Council member for the Society of Endocrinology (1999-2002), Editor Endocrinologist (2001-2004), Chair of CaHASE (2002-2015), member of the Bioscientifica Board (2006-2010), Society for Endocrinology Public Engagement Committee (2008-2011) and Nominations Committee (2010-2012). Executive Committee of the European Society ofEndocrinology (2011-2015), Treasurer of the European Society of Endocrinology (2013-2015), The Growth Hormone Research Society Council (2011-2018), The Pituitary Society Board of Directors (2019-).He is currently Chief Scientific Officer and Director on the Board of Diurnal Group Plc.
Professor Ariel Weissman graduated the Hadassah-Hebrew University
Medical School in 1988. In 1994 he completed his residency in
Ob/Gyn at the Kaplan Medical Center, Rehovot, Israel.
Prof. Weissman then pursued a 2-year research and clinical fellowship
with Prof. Bob Casper at the Division of Reproductive Sciences,
Department of Obstetrics and Gynecology, University of Toronto,
Toronto, Canada.
Upon returning to Israel in 1998, Prof. Weissman joined the IVF unit
at the Department of Ob/Gyn, Wolfson Medical Center, Holon,
Tel Aviv University Sackler Faculty of Medicine where he currently
holds a position of a Full Professor.
Prof. Weissman has published numerous scientific papers in peer
reviewed journals and together with David Gardner PhD, Colin
Howles PhD, and Zeev Shoham M.D., he published 5 editions of
“Textbook of Assisted Techniques: Laboratory and Clinical Perspectives”,
which is one of the leading books in the field of ART.